Evidence map›Paper›PMID 24148783›Full record

ArticleGenome biology2013

The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models.

Jennifer Yen, Richard M White, David C Wedge, Peter Van Loo, Jeroen de Ridder, Amy Capper, Jennifer Richardson, David Jones, Keiran Raine, Ian R Watson and 30 more

Open access · goldAbstract read
In one paragraph

Article in Genome biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Zebrafish as a Model Organism for the Development of Drugs for Skin Cancer.International journal of molecular sciences · 2017
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

40 authors at 8 institutions in 4 countries.

Jennifer Yen
Richard M White
David C Wedge
Peter Van Loo
Jeroen de Ridder
Amy Capper
Jennifer Richardson
David Jones
Keiran Raine
Ian R Watson
Chang-Jiun Wu
Jiqiu Cheng
Iñigo Martincorena
Serena Nik-Zainal
Laura Mudie
Yves Moreau
John Marshall
Manasa Ramakrishna
Patrick Tarpey
Adam Shlien
Ian Whitmore
Steve Gamble
Calli Latimer
Erin Langdon
Charles Kaufman
Mike Dovey
Alison Taylor
Andy Menzies
Stuart McLaren
Sarah O'Meara
Adam Butler
Jon Teague
James Lister
Lynda Chin
Peter Campbell
David J Adams
Leonard I Zon
E Elizabeth Patton
Derek L Stemple
P Andy Futreal
Wellcome Sanger Institute · GBHarvard University · USThe University of Texas MD Anderson Cancer Center · USInstitute of Genetics and Cancer · GBKU Leuven · BEDelft University of Technology · NLMemorial Sloan Kettering Cancer Center · USVirginia Commonwealth University · US

Funding

Transcriptional mechanisms and melanomaP01CA163222 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Kai W Wucherpfennig · 2013 to 2026
$25.3M
Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M
CORE--ZEBRAFISHP30DK049216 · NIDDK · CHILDREN'S HOSPITAL BOSTON · PI ORKIN, STUART H · 1999 to 2015
$14.3M
Cancer Biology in the ZebrafishR01CA103846 · NCI · CHILDREN'S HOSPITAL BOSTON · PI ZON, LEONARD IRA · 2003 to 2022
$7.5M
Evolutionary dynamics of melanoma metastasisDP2CA186572 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI WHITE, RICHARD MARK · 2013 to 2013
$2.7M
Regulators of Melanocyte and Melanoma Cell IdentityK08AR061071 · NIAMS · BOSTON CHILDREN'S HOSPITAL · PI KAUFMAN, CHARLES KORE · 2011 to 2015
$641k
Cancer Research UK 13031Medical Research Council G120/875Medical Research Council MC_PC_U127585840Medical Research Council MC_U127585840NIAMS NIH HHS K08AR61071Wellcome Trust
6 · The paper itself

Abstract

backgroundMelanoma is the most deadly form of skin cancer. Expression of oncogenic BRAF or NRAS, which are frequently mutated in human melanomas, promote the formation of nevi but are not sufficient for tumorigenesis. Even with germline mutated p53, these engineered melanomas present with variable onset and pathology, implicating additional somatic mutations in a multi-hit tumorigenic process.

resultsTo decipher the genetics of these melanomas, we sequence the protein coding exons of 53 primary melanomas generated from several BRAF(V600E) or NRAS(Q61K) driven transgenic zebrafish lines. We find that engineered zebrafish melanomas show an overall low mutation burden, which has a strong, inverse association with the number of initiating germline drivers. Although tumors reveal distinct mutation spectrums, they show mostly C > T transitions without UV light exposure, and enrichment of mutations in melanogenesis, p53 and MAPK signaling. Importantly, a recurrent amplification occurring with pre-configured drivers BRAF(V600E) and p53-/- suggests a novel path of BRAF cooperativity through the protein kinase A pathway.

conclusionThis is the first analysis of a melanoma mutational landscape in the absence of UV light, where tumors manifest with remarkably low mutation burden and high heterogeneity. Genotype specific amplification of protein kinase A in cooperation with BRAF and p53 mutation suggests the involvement of melanogenesis in these tumors. This work is important for defining the spectrum of events in BRAF or NRAS driven melanoma in the absence of UV light, and for informed exploitation of models such as transgenic zebrafish to better understand mechanisms leading to human melanoma formation.

Indexed as

Genetic HeterogeneityMutationAnimalsAnimals, Genetically ModifiedDisease Models, AnimalDNA Copy Number VariationsGene AmplificationGene Knockout TechniquesHomozygoteINDEL MutationMelanomaPolymorphism, Single NucleotideRisk FactorsSequence DeletionUltraviolet RaysZebrafish

Identifiers

PMID24148783
PMCPMC3983654
OpenAlexW2110578850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.